Venmax drugs & pharmaceuticals Limited has disclosed to BSE that it does not meet the criteria to be classified as a 'Large Corporate' under SEBI's regulatory framework. The company made this disclosure on April 14, 2026, in compliance with SEBI operational circular requirements.

Regulatory Compliance Disclosure

The disclosure was made pursuant to SEBI Circular dated August 10, 2021, which pertains to fund raising by issuance of debt securities by large entities. The company also referenced SEBI Master Circular No. SEBI/HO/DDHS/PoD1/P/CIR/2024/54 dated May 22, 2024 in its communication to the exchange.

Company Status Confirmation

Venmax Drugs & Pharmaceuticals Limited confirmed that as on March 31, 2026, the company does not fulfill the criteria specified in SEBI's circular for Large Corporate classification. This determination affects the company's obligations regarding debt securities issuance and related regulatory requirements.

Corporate Information

The disclosure was signed by Priyanka Agarwal, Company Secretary & Compliance Officer, and submitted to BSE's Head of Listing Compliance Department. The company is headquartered in Hyderabad with its registered office located at Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally.

This disclosure ensures transparency regarding the company's regulatory status and compliance with SEBI guidelines for corporate classification and fund raising activities.

Venmax drugs & pharmaceuticals Limited has informed BSE Limited about its exemption from submitting the Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The notification was filed on April 14, 2026, citing regulatory provisions that provide relief to smaller listed entities.

Regulatory Exemption Details

The exemption is granted under Regulation 15(2)(b) of SEBI (LODR) Regulations 2015, which specifies that corporate governance provisions under Regulation 24A do not apply to certain categories of listed entities. The regulation provides clear thresholds for exemption based on company size and financial parameters.

Company's Compliance Status

Venmax Drugs & Pharmaceuticals Limited falls within the exemption parameters as its paid-up capital and turnover remain below the specified threshold limits under Regulation 15(2) of SEBI (LODR) Regulations 2015. This positioning allows the company to operate without the additional compliance burden of annual secretarial reporting requirements.

The communication was made in reference to SEBI Circular No. CIR/CFD/CMD1/27/2019 dated February 08, 2019, which provides detailed guidelines regarding the submission of Annual Secretarial Compliance Reports. The circular outlines the framework for compliance requirements and exemption criteria for listed entities.

Official Communication

Company Secretary and Compliance Officer Priyanka Agarwal signed the official communication to BSE Limited's Corporate Relationship Department. The notification ensures proper disclosure to the stock exchange regarding the company's compliance status and regulatory positioning.

The company requested BSE Limited to take note of this exemption status in their records, ensuring proper documentation of the regulatory relief applicable to the entity for the specified financial year.